Compounds studied against the cellular hallmarks of aging — mitochondrial function, the NAD+ axis, and telomere biology.
Longevity peptides are studied not for a single endpoint but against the underlying cellular processes that decline with age. In this catalog the cluster organizes around three mechanistic axes rather than the cosmetic "anti-aging" framing common elsewhere: mitochondrial bioenergetics, the NAD+ cofactor economy, and telomere/pineal biology. Evidence here is mixed and often early-stage, so this page is a research reference to mechanisms and directions — not a claim of efficacy, and not medical or dosing guidance.
The largest axis is mitochondrial function. Mitochondrial dysfunction is a recognized hallmark of aging, and several catalogued compounds target it directly: MOTS-c is a mitochondrially-encoded peptide studied for AMPK activation and metabolic-stress signaling, while SS-31 (elamipretide) concentrates in the inner mitochondrial membrane and binds cardiolipin, studied for stabilizing cristae architecture and electron-transport efficiency. SS-31 is the most clinically advanced entry in the category, with trials in primary mitochondrial myopathy and Barth syndrome.
The second axis is the NAD+ economy. NAD+ is an essential redox cofactor and substrate for sirtuins and PARPs, and its availability declines with age. The category includes NAD+ itself as a research reagent and 5-Amino-1MQ, an NNMT inhibitor studied for preserving cellular NAD+ and methyl-donor pools rather than supplementing the cofactor directly — two mechanistically different routes to the same metabolic endpoint, which is why both sit in this category.
The third axis is telomere and pineal biology. Epitalon is a synthetic tetrapeptide derived from the pineal peptide epithalamin; it is studied in a telomere-maintenance and circadian framework, though the telomerase-activation narrative often attached to it rests largely on earlier-stage and regionally-concentrated studies rather than broad randomized human data. We present it as a mechanistic hypothesis under investigation, not an established effect.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
View profileRecombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
View profileThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileMitochondria-targeted cardiolipin-binding tetrapeptide.
View profileSynthetic tetrapeptide investigated for telomerase activity and circadian effects.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileEssential redox cofactor central to mitochondrial bioenergetics and sirtuin activity.
View profileIn this catalog, a longevity peptide is a compound studied against a cellular hallmark of aging — most commonly mitochondrial dysfunction, NAD+ decline, or telomere attrition — rather than a cosmetic anti-aging product. Entries are mechanistic reference profiles, not products or treatment recommendations.
Both target mitochondria but differently. MOTS-c is a mitochondrially-encoded peptide studied for AMPK activation and metabolic-stress signaling; SS-31 (elamipretide) is a cardiolipin-binding tetrapeptide studied for stabilizing inner-membrane cristae and electron-transport efficiency. SS-31 is the more clinically advanced of the two.
No. Epitalon is studied within a telomere-maintenance and circadian framework, but the telomerase-activation narrative rests largely on earlier-stage and regionally-concentrated research rather than broad randomized human trials. We present it as a mechanistic hypothesis under investigation, not an established effect.
No. AmericanPeptide.com is a computational research and reference platform, not a medical device or clinical decision-support system. Nothing here is medical advice, a dosing protocol, or an offer to sell. Independent expert and regulatory review is required before any experimental use.